Missing data in confirmatory clinical trials

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 6, 2009, Pages 969-979

  Flyer, Paul ^a   Hirman, Joseph ^a  

^a Pacific Northwest Statistical Consulting   (United States)

Author keywords

Imputation; Intention to treat; LOCF; Missing at random; Missing data; Noncompliance; Repeated measures

Indexed keywords

CLINICAL RESEARCH; DATA ANALYSIS; INFORMATION PROCESSING; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; STATISTICAL MODEL;

CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; ENDPOINT DETERMINATION; HUMANS; RESEARCH DESIGN;

EID: 75749157804     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400903242746     Document Type: Review

References (17)

1. Bhore, R. (2002). Statistical Review and Evaluation-Lopinavir/ritonavir. Food and Drug Administration NDA 21-226/21-251. http://www.fda.gov/cder/foi/nda/ 2002/ 21-226S003-Kaletra-statr.pdf
2. Committee for Medicinal Produces for Human Use, European Medicines Agency. (2008). Guideline on Clinical Investigation of Immunosuppressants for Solid Organ Transplantation. http://www.emea.europa.eu/pdfs/human/ewp/ 26314806enfin.pdf.
3. Dixon, C. (1999). Statistical Review and Evaluation-Sirolimus. Food and Drug Administration NDA 21-083. http://www.fda.gov/cder/foi/nda/99/21083A- Rapamune-statr.pdf
4. European Agency for the Evaluation of Medicinal Products, Evaluation of Medicines for Human Use. (2002). Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus. http://www.emea. europa.eu/pdfs/ human/ewp/108000en.pdf
5. Food and Drug Administration. (1990). Guideline for the Clinical Evaluation of Lipid-Altering Agents in Adults and Children. http://www.fda.gov/ cder/guidance/ lipid.pdf
6. Food and Drug Administration. (1998). Guidance for Industry. Developing Antimicrobial Drugs-General Considerations for Clinical Trials-Draft Guidance. http://www.fda.gov/cder/guidance/2580dft.pdf
7. Food and Drug Administration. (2002). Guidance for Industry. Antiretroviral Drugs Using Plasma HIV RNA Measurements-Clinical Considerations for Accelerated and Traditional Approval. http://www.fda.gov/cder/guidance/ 3647fnl.pdf
8. Food and Drug Administration. (2007). Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. http://www.fda.gov/ cder/guidance/7478fnl.pdf
9. Food and Drug Administration. (2008). Guidance for Industry. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention-Draft Guidance. http://www.fda.gov/cder/guidance/7630dft.pdf
10. Gabry, K. E. (2005). Clinical Review-Exenatide Injection. Food and Drug Administration NDA 21-733. http://www.fda.gov/cder/foi/nda/2005/021773-Byetta- medr.PDF
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (1998). Harmonised Tripartite Guideline, Statistical Principles for Clinical Trials, E9. http://www.ich.org/ LOB/media/MEDIA485.pdf
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (2000). Draft ICH Consensus Principle, Principles for Clinical Evaluation of New Antihypertensive Drugs, E12A. http://www. ich.org/LOB/media/MEDIA488.pdf
13. Liu, C. (2003). Statistical Review and Evaluation-Rosuvastatin Calcium. Food and Drug Administration NDA 21-366. http://www.fda.gov/cder/foi/nda/2003/ 21-366- Crestor-Statr-P2.pdf
14. Massie, T. (2002). Statistical Review and Evaluation-Memantine. Food and Drug Administration NDA 21-487. http://www.fda.gov/cder/foi/nda/2003/21-487- Namenda-Statr.pdf.
15. Mele, J. (2003). Statistical Review and Evaluation-Cinacalcet HCI. Food and Drug Administration NDA 21-688. http://www.fda.gov/cder/foi/nda/2004/21-688. pdf- Sensipar-Statr.pdf
16. Mulinde, J. (2006). Clinical Team Leader Memo-Retapamulin Ointment, 1%. Food and Drug Administration NDA 22-055. http://www.fda.gov/cder/foi/nda/2007/ 022055s000-MedR.pdf
17. Shan, S.-M. (2007). Statistical Review and Evaluation-Temsirolimus. Food and Drug Administration NDA 22-088. http://www.fda.gov/cder/foi/nda/2007/ 022088s000-StatR.pdf